Medical food

Todos Medical Announces Insolvency Proceedings in Israel

Retrieved on: 
Friday, December 22, 2023
Long, Todos, Annual report, Form, TEL, Form S-1, Court, Medical food, Hamas, Element, NLC, COVID, OTCQB, Trustee, ALS, Hearing

Due to unforeseen setbacks and adverse market conditions during the listing process, the Company was unable to effect the NYSE American and related public offering.

Key Points: 
  • Due to unforeseen setbacks and adverse market conditions during the listing process, the Company was unable to effect the NYSE American and related public offering.
  • The Company made the first payment, of $24,000, to Mr. ZIgdon in January 2023.
  • In December 2023, a trustee was appointed by the Court of Insolvency to oversee the liquidation of Todos Medical Ltd. in Israel.
  • Regardless of the outcome of the matters before the Court of Insolvency in Israel, Todos Medical and NLC Pharma are committed to ensuring that all customers who have placed orders for Tollovid via www.mytollovid.com will receive their orders.

Lobe Sciences Announces Commercial Distribution Agreement With Pentec Health for US Launch of Altemia™

Retrieved on: 
Wednesday, May 17, 2023
Biotechnology, Technology, Managed Care, Health, Pharmaceutical, Neurology, Research, Fitness & Nutrition, Science, Clinical Trials, Food Tech, Partnership, CSE, DHA, SCD, Biomarker, Lobe, CGMP, Patient, Sickle cell disease, United, Caregiver, Medical food, Pharmaceutical industry, Nursing

Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat orphan diseases today announced it has entered into a commercial distribution agreement for the supply and distribution of Altemia™ with Pentec Health, Inc. (“Pentec Health”), a nationwide provider of clinical nutrition and specialty care services addressing complex needs for patients.

Key Points: 
  • Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat orphan diseases today announced it has entered into a commercial distribution agreement for the supply and distribution of Altemia™ with Pentec Health, Inc. (“Pentec Health”), a nationwide provider of clinical nutrition and specialty care services addressing complex needs for patients.
  • Under the terms of the distribution agreement, Pentec Health will receive the exclusive rights to distribute Altemia™ in the United States and US territories.
  • Through Pentec Health, Altemia™ will be available to pediatric and adult patients with SCD throughout the United States.
  • Pentec Health is extremely well-positioned and experienced in the medical food marketplace and they will ensure it reaches key healthcare providers and patients.

KetamineOne Subsidiary KGK Science Helps Client Receive New Dietary Ingredient Status from U.S. FDA

Retrieved on: 
Thursday, December 2, 2021
COPD, Disclosure, MEDI, FRA, Lipid, Database, GLOBE, Ketamine, Dietary supplement, NDI, Salmon, Calcium, Security (finance), Mental health, Publication, Achievement, Eosinophil, SPH, Asthma, Research, OTC, Science, NEO, Review, Protein, Produce traceability, Cannabis, FD, Health, Collagen, KGK, Goal, Hydrolysis, Federal Food, Drug, and Cosmetic Act, Phosphorus, DHA, FDA, Medical food, Element, Quality of life, EPA, Safety, Technology, Industry, Inflammation, HBC, Ulcerative colitis, Natural Resources, Aquaculture, Pharmaceutical industry

The two letters that HBC received for CalGo and OmeGo are the highest safety rating and attestation the company could have received from the FDA.

Key Points: 
  • The two letters that HBC received for CalGo and OmeGo are the highest safety rating and attestation the company could have received from the FDA.
  • HBC is now part of an exclusive list of companies that have successfully obtained NDI status with the FDA for their novel dietary ingredients contained in these two nutritional supplements.
  • Approximately 50 NDI ingredients are reviewed annually by the FDA but historically only around 30% have received an FDA Acknowledgement (AKL) letter.
  • As a valued client of KGK, HBC has a novel and innovative technology for extracting nutritional components from Atlantic salmon in a very sustainable way.

Clinical Nutrition Market - Global Outlook and Forecast 2021-2026 with Abbott Laboratories, Baxter International, B. Braun, Danone, and Nestle Health Science Dominating - ResearchAndMarkets.com

Retrieved on: 
Monday, July 19, 2021
General Health, Pharmaceutical, Health, Food and drink, Companies, Industry economics), Medical food, Nutricia, Danone, European Society for Clinical Nutrition and Metabolism, Fresenius, Nestlé, Clinical nutrition, Wellness

The global clinical nutrition market research report includes a detailed segmentation by route of administration, age group, product type, application, distributional channels, end-users, geography.

Key Points: 
  • The global clinical nutrition market research report includes a detailed segmentation by route of administration, age group, product type, application, distributional channels, end-users, geography.
  • Focusing on health and wellness, aging well, and disease prevention by consumers, healthcare providers are demanding preventive clinical nutrition products and are experiencing rapid growth.
  • Global brands such as Abbott, Nestle, Nutricia, and Fresenius Kabi offer parenteral, enteral, and oral nutrition products for infants.
  • Abbott Laboratories, Baxter International, B. Braun, Danone, and Nestle Health Science are the major players.

All Real Nutrition Partners with PlasticBank to Clean Up the Oceans

Retrieved on: 
Monday, July 12, 2021
Medical food, Food and drink

Ever since its inception, All Real Nutrition has been focused on three things.

Key Points: 
  • Ever since its inception, All Real Nutrition has been focused on three things.
  • While these efforts have helped All Real Nutrition operate responsibly at home, though, the company is taking its community-focused sustainability message abroad through its latest decision to support the non-profit PlasticBank.
  • Every All Real Nutrition sale contributes to this effort, with each bar equating to two bottles being removed from the water.
  • About All Real Nutrition: All Real Nutrition was officially launched in late 2020 and is headquartered in Kerry, Ireland.

Danone Manifesto Ventures Acquires Majority Stake in Harmless Harvest

Retrieved on: 
Wednesday, June 30, 2021
Professional services, Health, Supermarket, Specialty, Other Natural Resources, Food, Beverage, Natural Resources, Retail, Fitness & Nutrition, Environment, Finance, Food and drink, Plants, Organisms, CAC 40, Danone, Medical food, Coconut, Yogurt, Danone Manifesto Ventures, Harmless Harvest, DANONE MANIFESTO VENTURES, HARMLESS HARVEST

Danone Manifesto Ventures (DMV) today announced that it has acquired a majority stake in Harmless Harvest, a leader in organic coconut-based products including coconut water and dairy-free coconut yogurt alternatives, as DMV furthers its investment position and partnership efforts.

Key Points: 
  • Danone Manifesto Ventures (DMV) today announced that it has acquired a majority stake in Harmless Harvest, a leader in organic coconut-based products including coconut water and dairy-free coconut yogurt alternatives, as DMV furthers its investment position and partnership efforts.
  • View the full release here: https://www.businesswire.com/news/home/20210630005652/en/
    Harmless Harvest Organic Coconut Water (Photo: Business Wire)
    In 2017, Danone Manifesto Ventures led a $30 million capital growth round in the company, alongside Mousse Partners and other investors.
  • With this additional investment, DMV acquires majority ownership and will continue to provide financial, strategic, and operational support in all appropriate business areas while Harmless Harvest continues to operate independently.
  • DMVs majority stake in Harmless Harvest supports Danones global efforts to accelerate the growth of its plant-based business and offer more plant-based options to consumers throughout their day.

Poka Closes $25M Series B Round to Connect and Empower Frontline Factory Workers Across Global Manufacturers

Retrieved on: 
Monday, June 7, 2021
Data management, Technology, Manufacturing, Software, Networks, Other Manufacturing, Internet, Companies, Industry economics), Food and drink, CAC 40, Danone, Medical food, Tetra Pak, Poka, Robert Bosch GmbH, Poka, 40 North Ventures, McRock Capital, POKA, 40 NORTH VENTURES, MCROCK CAPITAL

Poka, a leading connected worker platform built specifically for manufacturers, has raised $25 million in Series B financing in support of the companys next phase of growth.

Key Points: 
  • Poka, a leading connected worker platform built specifically for manufacturers, has raised $25 million in Series B financing in support of the companys next phase of growth.
  • Poka helps address these challenges by giving factory workers the ability to learn continuously and solve problems more autonomously at the point of need.
  • The funding will also expedite Pokas ability to better serve its growing global customer base by scaling its go-to-market teams.
  • Poka is trusted by leading global manufacturers including Nestl, Danone, Bosch, Kraft, Johnson & Johnson, and Tetra Pak.

Guardion Health Sciences Announces Appointment of Craig J. Sheehan as Chief Commercial Officer

Retrieved on: 
Thursday, June 3, 2021
Clinical nutrition, GHSI, Medical food, European Society for Clinical Nutrition and Metabolism

SAN DIEGO, June 03, 2021 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (Guardion or the Company), a clinical nutrition and diagnostics company that develops clinically supported nutrition, supplements, medical foods and medical devices, today announced the appointment of Craig J. Sheehan as its Chief Commercial Officer.

Key Points: 
  • SAN DIEGO, June 03, 2021 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (Guardion or the Company), a clinical nutrition and diagnostics company that develops clinically supported nutrition, supplements, medical foods and medical devices, today announced the appointment of Craig J. Sheehan as its Chief Commercial Officer.
  • Mr. Sheehan joins Guardion following the Companys recent acquisition of Activ Nutritional.
  • I thank the team at Guardion for the opportunity to build toward success together, added Mr. Sheehan.
  • Guardion Health Sciences, Inc. (Nasdaq: GHSI), is a clinical nutrition and diagnostics company.

Guardion Health Sciences to Present at the LD Micro Virtual Invitational Conference on June 9, 2021

Retrieved on: 
Wednesday, June 2, 2021
Clinical nutrition, European Society for Clinical Nutrition and Metabolism, Medical food, GHSI

SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI), a clinical nutrition and diagnostics company that develops clinically supported nutrition, supplements, medical foods, and medical devices, announced today that Chief Executive Officer Bret Scholtes will present a corporate overview at the three-day LD Micro Virtual Invitational Conference being held on June 8 10, 2021.

Key Points: 
  • SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI), a clinical nutrition and diagnostics company that develops clinically supported nutrition, supplements, medical foods, and medical devices, announced today that Chief Executive Officer Bret Scholtes will present a corporate overview at the three-day LD Micro Virtual Invitational Conference being held on June 8 10, 2021.
  • Mr. Scholtes will deliver his corporate presentation on June 9 at 12:30pm ET, Track 2.
  • Guardion Health Sciences, Inc. (NASDAQ: GHSI), is a clinical nutrition and diagnostics company.
  • Guardion offers a portfolio of science-based, clinically supported nutrition, supplements, medical foods, and diagnostic products that support healthcare professionals, their patients, and consumers in achieving health goals.

Lexaria DehydraTECH(TM) 2.0 Outperforms MCT in 2021 R&D Study

Retrieved on: 
Tuesday, May 25, 2021
Psychoactive drugs, Dosage forms, Medical food, Medium-chain triglyceride, Triglycerides, MCT, Nicotine, Formulation

They recently released R&D study results for three new DehydraTECHTM 2.0 formulation variations that significantly outperformed traditional MCT oil-based formulations that have become CBD industry standard.

Key Points: 
  • They recently released R&D study results for three new DehydraTECHTM 2.0 formulation variations that significantly outperformed traditional MCT oil-based formulations that have become CBD industry standard.
  • Though new to NASDAQ, Lexaria Bioscience Corp. has been producing positive test results with their patented DehydraTECHTM bio-absorption technology since 2016.
  • But now, test results from May of 2021 showed a CBD delivery rate that was up to 2,708% stronger than medium chain triglyceride (MCT) oils which have become industry standard.
  • In November of 2020, Lexaria published a list of 2021 strategic initiatives that also targets hypertension treatment, nicotine delivery, and antiviral absorption.